Related Experiment Video
Updated: Dec 6, 2025
Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice
Published on: August 25, 2023
State of the Art: No-Reflow Phenomenon
Gianluca Caiazzo1, Rita Leonarda Musci2, Lara Frediani3
1ICCU, San Giuseppe Moscati Hospital, ASL CE, Via Gramsci 1, Aversa 81031, Italy.
Insights
Primary percutaneous coronary intervention is key for heart attacks. This review covers strategies to improve blood flow when blockages persist after treatment, aiding recovery.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Primary percutaneous coronary intervention is the standard treatment for ST-elevation myocardial infarction.
- No-reflow phenomenon involves poor heart muscle perfusion despite open arteries.
- Existing treatments for no-reflow include pharmacologic and device-based methods.
Purpose of the Study:
- To provide an updated overview of the no-reflow phenomenon.
- To discuss current clinical evidence for no-reflow therapies.
- To explore ongoing investigations into novel strategies for managing no-reflow.
Main Methods:
- Literature review of clinical evidence.
- Analysis of existing therapeutic strategies.
- Discussion of ongoing research and novel interventions.
Main Results:
- No-reflow remains a challenge in acute myocardial infarction management.
- Various pharmacologic and device-based approaches have been investigated.
- Further research is needed to optimize treatment strategies.
Conclusions:
- No-reflow requires effective management strategies beyond initial reperfusion.
- Both established and emerging therapies are crucial for improving outcomes.
- Continued investigation into novel treatments is essential for addressing this complication.
Abstract:
Primary percutaneous coronary intervention is the preferred reperfusion strategy for the management of acute ST-segment elevation myocardial infarction. No reflow is characterized by the inadequate myocardial perfusion of a given segment without angiographic evidence of persistent mechanical obstruction of epicardial vessels. Both pharmacologic and device-based strategies have been tested to resolve coronary no reflow. This article provides an updated overview of the no-reflow phenomenon, discussing clinical evidence and ongoing investigations of existing and novel therapeutic strategies to counteract it.
